These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24922656)

  • 21. Apigenin impairs oral squamous cell carcinoma growth in vitro inducing cell cycle arrest and apoptosis.
    Maggioni D; Garavello W; Rigolio R; Pignataro L; Gaini R; Nicolini G
    Int J Oncol; 2013 Nov; 43(5):1675-82. PubMed ID: 23969487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Torin2 enhances the radiosensitivity of MCF‑7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylation.
    Luo J; Pi G; Xiao H; Ye Y; Li Q; Zhao L; Huang H; Luo H; Zhang Q; Wang D; Wang G
    Mol Med Rep; 2018 Jan; 17(1):366-373. PubMed ID: 29115478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
    Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
    Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
    Zitzmann K; De Toni EN; Brand S; Göke B; Meinecke J; Spöttl G; Meyer HH; Auernhammer CJ
    Neuroendocrinology; 2007; 85(1):54-60. PubMed ID: 17310129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Kim SY; Jeong EH; Lee TG; Kim HR; Kim CH
    Anticancer Res; 2021 Jun; 41(6):2885-2894. PubMed ID: 34083279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D(3) to induce growth arrest and differentiation of AML cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Ni L; Koeffler HP; Yokoyama A
    Exp Hematol; 2010 Aug; 38(8):666-76. PubMed ID: 20382200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
    Li J; Xue L; Hao H; Han Y; Yang J; Luo J
    Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
    Wedel S; Hudak L; Seibel JM; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
    Life Sci; 2011 Feb; 88(9-10):418-24. PubMed ID: 21192952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
    Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
    Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
    Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
    Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
    Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanism underlying pancreatic cancer cell resistance to mTOR inhibitor RAD001 via c-Raf/ERK1/2 activation].
    Wei F; Zhang P; Qi J; Wang M; Wang G
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jan; 30(1):23-7. PubMed ID: 24405594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor effect of the mammalian target of rapamycin inhibitor everolimus in oral squamous cell carcinoma.
    Naruse T; Yanamoto S; Yamada S; Rokutanda S; Kawakita A; Kawasaki G; Umeda M
    Pathol Oncol Res; 2015 Jul; 21(3):765-73. PubMed ID: 25682238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The miR-15 family enhances the radiosensitivity of breast cancer cells by targeting G2 checkpoints.
    Mei Z; Su T; Ye J; Yang C; Zhang S; Xie C
    Radiat Res; 2015 Feb; 183(2):196-207. PubMed ID: 25594541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
    Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
    Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
    Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
    Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human esophageal squamous carcinoma cells.
    Liu KS; Zhang Y; Ding WC; Wang SX; Xiang YF; Yang P; Chen ZP; Zheng K; Liu Z; Xia M; Wang YF
    Int J Oncol; 2012 Dec; 41(6):2276-84. PubMed ID: 23076967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The dietary phytochemical 3,3'-diindolylmethane induces G2/M arrest and apoptosis in oral squamous cell carcinoma by modulating Akt-NF-κB, MAPK, and p53 signaling.
    Weng JR; Bai LY; Chiu CF; Wang YC; Tsai MH
    Chem Biol Interact; 2012 Feb; 195(3):224-30. PubMed ID: 22290291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.